DIRECTORS AND SENIOR MANAGEMENT

Ms. Hsu has held directorships in the following listed and private companies outside of

the Group during the past three years:

(cid:129)

(cid:129)

(cid:129)

(cid:129)

Corelle Brands as a non-executive director;

ACEA Bioscience as a non-executive director;

Weconex as a non-executive director; and

Mindray Medical International Limited (a company listed on the New York Stock
Exchange with ticker symbol MR) as a director.

Ms. Hsu received her bachelor of science in business administration degree from the

University of California at Berkeley in May 1998.

Mr. Kaixian Chen, Ph.D., aged 72, is an independent non-executive Director. He is
responsible for providing independent opinion and judgment to the Board. Dr. Chen has been
a professor of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, since
1990, served as its director between 1996 and 2004, and has served as director of its degree
committee since 2014. He has also been a professor of the Shanghai University of Traditional
Chinese Medicine since 2005, served as its president from 2005 to 2014, and has served as
chairman of its academic committee from 2014 to 2018.

Dr. Chen holds professional memberships and qualifications in different capacities in

numerous organizations in the PRC, including the below:

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

as an Academician of the Chinese Academy of Sciences (中國科學院) since 1999;

as deputy president of the Chinese Pharmaceutical Association (中國藥學會) from
2007 to 2017, and the Director of the Division of Medicinal Chemistry, CPA (中國
藥學會藥物化學專業委員會) since 2007;

as member of the general expert group of the National Science and Technology
Major Project “Innovative Drug Research & Development” (國家重大科技專項《重
大新藥創制》) since 2008, and the deputy chief scientific and technical officer since
2016;

as chairman of the Shanghai Association of Science and Technology (上海市科學技
術協會) since 2011;

as editor in chief of Progress in Pharmaceutical Sciences, Chinese Journal of New
Drugs and Clinical Remedies (藥學進展、中國新藥與臨床雜誌) since 2015; and

– 374 –

